1. Background {#sec1}
=============

Alzheimer\'s disease (AD) pathophysiology is characterized by amyloid beta (Aβ) accumulation, tau hyperphosphorylation, and neurodegeneration, ultimately leading to cognitive decline [@bib1]. In addition, vascular changes are involved in AD pathophysiology. Vascular changes, either intrinsic or as copathology, interact with AD pathology, neurodegeneration, and cognitive impairment [@bib2], [@bib3] and are described with the term vascular cognitive impairment (VCI) [@bib4], [@bib5]. Vascular pathology is prevalent and described at autopsy in up to 75% of dementia cases [@bib4], [@bib6]. Vascular changes include white matter hyperintensities (WMHs) as a result of chronic (subcortical) ischemia of small vessels, large vessel infarcts, lacunar infarcts (e.g. thalamus), arteriosclerosis and atherosclerosis, and cerebral amyloid angiopathy (CAA) [@bib7], [@bib8]. CAA is an intravascular pathology in which Aβ is deposited in the vessel wall and is associated with microhemorrhages and microinfarcts [@bib9]. Its prevalence is between 20% and 40% in nondemented elderly and 50-60% in demented elderly in autopsy studies [@bib10], [@bib9]. A strong correlation between AD and CAA exists, as in postmortem AD brains, in 85-95% of the cases CAA is found [@bib9]. Moreover, recent studies also showed that decreased cerebral blood flow and blood-brain barrier alterations might be involved in AD pathophysiology, possibly playing a role in Aβ clearance [@bib2], [@bib3]. Currently used biomarkers for vascular changes are limited to magnetic resonance imaging (MRI) [@bib8]. To better understand and measure vascular changes in AD, new biomarkers for vascular changes might increase pathophysiological insight and could complement the currently used ATN system for amyloid(A), tau(T), and neurodegeneration(N) [@bib11].

The retina is a possible source of vascular biomarkers as retinal vasculature can be imaged noninvasively at the micrometer level using different imaging modalities, including fundus photography, measurements of choroidal thickness (using enhanced depth imaging optical coherence tomography (EDI-OCT) and OCT angiography (OCTA). Vascular changes in the retina have been described in AD, including changes in vascular parameters from fundus photography analysis, using Singapore I Vessel analysis (SIVA) software, such as increased venous diameter, decreased arterial diameter, and decreased fractional dimension [@bib12]. In contrast, a recent report showed an absence of group differences between AD patients and control participants, while showing decreased total and arteriolar fractal dimensions in VCI cases [@bib13]. In addition, choroidal thinning in AD is reported in several studies using EDI-OCT [@bib14], [@bib15], [@bib16], [@bib17]. Recent reports on retinal vasculature with OCTA reported increased foveal avascular zone (FAZ) size and decreased vessel density and flow in AD [@bib18], [@bib19] and preclinical AD [@bib20].

As ophthalmological comorbidity could potentially influence retinal vascular measurements and is often asymptomatic, a thorough ophthalmological screening is warranted. Second, assessing retinal biomarkers in patients with a confirmed AD diagnosis by established biomarkers such as cortical atrophy, amyloid and tau in cerebrospinal fluid (CSF) or amyloid positron emission tomography (PET) supports the clinical diagnosis on one hand and allows comparison of the new biomarkers to the gold standard on the other hand.

The aim of this study was to identify retinal vascular biomarkers as possible noninvasive biomarkers in AD. Following previous publications, we hypothesize to find increased central retinal artery equivalent (CRAE), decreased central retinal vein equivalent (CRVE), decreased fractal dimension, thinner choroidal thickness, smaller vessel density, and larger FAZ in AD compared to control cases. We, therefore, measured retinal vascular parameters using fundus photography, EDI-OCT, and OCTA in well-characterized amyloid-positive AD cases, while taking ophthalmological confounders into account. In addition, we assessed relationships between retinal vascular parameters and WMHs on MRI.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

We assessed 50 AD patients and 38 control subjects from the Amsterdam Dementia Cohort (ADC) that were enrolled into our retinal imaging cohort as described earlier (all Mini-Mental State Examination (MMSE) ≥17, capable of giving informed consent) [@bib21]. In brief, all patients and control subjects underwent a standardized screening protocol including (medical) history, neuropsychological examination, blood draw for apolipoprotein E ε4/ε4 (APOE ε4/ε4) genotype, blood pressure measurements, neuroimaging, and lumbar puncture [@bib22]. All patients met National Institute on Aging and Alzheimer\'s Association criteria of AD and had evidence of amyloid pathology based on CSF analysis or amyloid PET [@bib11]. Controls were subjects with cognitive complaints that showed no evidence of objective cognitive impairment, neurodegeneration, or amyloid pathology based on amyloid PET or CSF analysis.

2.2. MRI scanning {#sec2.2}
-----------------

MRI scans were reviewed by an experienced and blinded rater (FB) before the multidisciplinary meeting of the ADC, where a clinical diagnosis was made by consensus. Visual rating scores for atrophy on MRI were determined based on T1-weighted images and included medial temporal lobe atrophy, global cortical atrophy, and parietal cortical atrophy [@bib23], [@bib24], [@bib25]. Vascular assessment included Fazekas score for white matter hyperintensities (fluid attenuation inversion recovery sequence), assessment of lacunar infarcts (fluid attenuation inversion recovery, T2-weighted sequences), and microbleeds (T2\*-sequence) [@bib26].

2.3. Cerebrospinal fluid analysis {#sec2.3}
---------------------------------

CSF was analyzed using Innotest ELISA and measured amyloid-beta~-1-42~(Aβ~1-42~), tau~-181~, and phosphorylated Tau (pTau). A tau~-181~/Aβ~1-42~ ratio ≥.52 was considered an AD profile [@bib27].

2.4. Amyloid PET analysis {#sec2.4}
-------------------------

A subset of cases was enrolled in research programs that included amyloid PET scanning with the following tracers: ^18^F-Florbetaben (NeuraCeq) (n = 24), ^18^F-Florbetapir (Amyvid) (n = 9), and Pittsburgh compound (^11^C-PIB) (n = 3). Parametric standardized uptake value images of amyloid PET scans were assessed by an experienced rater (BvB) and visually interpreted as amyloid positive or amyloid negative following guidelines for individual tracers.

2.5. Ophthalmological assessment {#sec2.5}
--------------------------------

Subjects were included within a year after the ADC diagnostic screening program and underwent the following eye examinations to exclude possible confounding ophthalmological pathology: best-corrected visual acuity, intraocular pressure using noncontact tonometry (if intraocular pressure \>20 mmHg, we used contact applanation tonometry), slit-lamp examination of the anterior and posterior segment, Heidelberg retinal tomography optic nerve head (ONH) analysis, and frequency doubling technology for visual fields. Tropicamide (0.5%) was administrated for pupil dilation to facilitate optimal ophthalmic examination. We followed the fourth European Glaucoma Guideline criteria: glaucoma was diagnosed when two of the three following measurements were abnormal: ocular pressure (\>21 mmHg), structural glaucomatous changes (examined with Heidelberg retinal tomography using the Moorfields regression analysis), and functional changes (examined with frequency doubling technology) [@bib28]. All examinations were interpreted by an experienced ophthalmologist (FDV). Exclusion criteria were ophthalmological conditions interfering with imaging or retinal vasculature, such as severe cataract, age-related macular degeneration, and glaucoma or systemic conditions such as diabetes mellitus.

2.6. Retinal vascular imaging {#sec2.6}
-----------------------------

Retinal vasculature was measured by personnel blinded for diagnosis, using three imaging modalities: (1) fundus photography, (2) enhanced depth imaging OCT (EDI-OCT) and (3) OCT angiography (OCTA) ([Fig. 1](#fig1){ref-type="fig"}). Digital fundus images of 50° field of view of the macula and ONH were obtained using a Topcon TRC 50DX type IA (Topcon Medical Systems, Inc., Oakland, CA, USA). Macular photographs were assessed for incident pathology by an experienced ophthalmologist (FDV), whereas ONH photographs were used for SIVA analyses (version 3.0; National University of Singapore, Singapore) [@bib29], [@bib30], [@bib31] by two trained raters (JdH, JAvdK). Values from both eyes of every participant were averaged; if only one suitable image was present, only this eye was included (n = 3). We assessed vascular parameters that were earlier found to have high intraobserver intraclass correlation (\>0.80) [@bib32], namely CRAE, CRVE, arteriole-to-venule ratio, fractal dimension of the arteriolar network (FDa), fractal dimension of the venular network, curvature tortuosity of the arterioles (cTORTa), and curvature tortuosity of the venules. We averaged vascular parameters of two raters. Intraobserver intraclass correlation coefficients of the present study are shown in [Supplementary Table 1](#appsec1){ref-type="sec"}.Fig. 1Overview of retinal modalities to assess microvasculature. Retinal vasculature was assessed using three imaging modalities: retinal vascular parameter analysis using SIVA applied on fundus photographs (red), choroidal thickness measurements using enhanced depth imaging optical coherence tomography (EDI-OCT) (green), and vessel density and foveal avascular zone (FAZ) measured with OCT angiography (OCTA) (yellow). Abbreviations: OCT, optical coherence tomography; SIVA, Singapore I Vessel analysis.

EDI-OCT scans were acquired with a Heidelberg Spectralis spectral domain-OCT, using the following protocol: central retina (macula) fast horizontal scanning; central 20° × 20° area; 25 B-scans (averaging 9 frames per b-scan); 512 a-scans per b-scan. Manual measurements of choroidal thickness were performed in five evenly distributed b-scans per macular volume scan ([Supplementary Fig. 1](#appsec1){ref-type="sec"}) [@bib14], [@bib16], [@bib17]. Five measurements per b-scan were performed: foveal, 1 mm nasal and temporal from the fovea and 2 mm nasal and temporal from the fovea. The anterior boundary of the choroid layer was defined as the hyperreflective band corresponding to the retinal pigment epithelium---Bruch\'s membrane complex. To define the posterior boundary, each measurement point was categorized based on the presence or absence of the choroidal-scleral interface as a hyperreflective band, the suprachoroidal space as a hyporeflecting band, and/or a smooth line marking the posterior boundary on the OCT image. The posterior boundary was then defined as the outer limit of the choroidal-scleral interface, the inner limit of the suprachoroidal space, or the smooth line. If no clear boundary was identifiable over the length of the scan, the image was defined as ungradable. The averages of the measurements (n = 25) from both eyes were used for analysis of mean choroidal thickness.

OCTA was acquired using a Zeiss Model 5000 spectral domain-OCT with Angioplex and consisted of 6 × 6 mm scans of the macula, 350 b-scans each. Vascular density measured in the inner ring (Ø 1-3 mm around fovea) and outer ring (Ø 3-6 mm around fovea) of the Early Treatment in Diabetes Retinopathy Study grid. FAZ surface area was measured. Scans were visually assessed for quality. All scans had quality factors ≥7/10 and could be considered "good" quality.

2.7. Statistical analysis {#sec2.7}
-------------------------

### 2.7.1. Power calculation {#sec2.7.1}

Based on a previous meta-analysis [@bib12], comparing 374 AD cases compared to 707 control subjects, a decrease of 7.52 μm in CRAE can be expected. Assuming a true effect of 7.52 μm and a standard deviation of ≈15 μm, 28 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. In addition, from the same meta-analysis a decrease of 10.74 μm in CRVE can be expected. Assuming a true effect of 10.74 μm and a standard deviation of ≈15 μm, 15 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. From a previous report [@bib16], a decrease of ≈60 μm in choroidal thickness can be expected. Assuming a true effect of 60 μm and a standard deviation of ≈50 μm, 6 subjects in each group are needed to reject the null hypothesis of no difference between the disease and control group with a power of 0.80. We included \>35 participants per disease group.

### 2.7.2. Data analysis {#sec2.7.2}

Data were visually tested for a normal distribution using histograms and Q-Q plots. Measures that were normally distributed were tested with an independent t-test, nonnormally distributed measures with a Mann-Whitney U test, and binary variables with a chi-squared test. Linear regression models were used to assess if changes in retinal vasculature (dependent) were attributable to diagnosis (independent) or age, sex, spherical equivalent, quality factor, and/or hypertension (covariates). All betas reported are standardized betas. Stratified analysis for APOE ε4/ε4 genotype carriers versus noncarriers was performed for retinal vascular parameters. Intraobserver intraclass correlation (absolute agreement) was calculated to test intrarater variability for SIVA. Data analysis was performed with IBM SPSS Statistics (version 22.0).

3. Results {#sec3}
==========

[Table 1](#tbl1){ref-type="table"} shows cohort characteristics. We included 50 AD patients and 38 control subjects from our retinal imaging [@bib21] cohort with retinal vasculature imaging available. One AD case was excluded because of glaucoma. In addition, we excluded one AD case that was later found to have a progranulin mutation, a mutation known to directly affect retinal integrity [@bib33]. As a result, fundus photographs were available in 48 AD patients and 38 control participants. EDI-OCT and OCTA became available in the course of the study and were obtained in 41 AD patients and 31 control participants for EDI-OCT and 26 AD patients and 31 control participants for OCTA. AD cases were slightly older (65.4 y vs. 60.6 y, *P* \< .01) and had MMSE and MRI atrophy scores indicative of an AD diagnosis. There was no difference between groups for WMH and lacunes indicating similar cerebrovascular loading. By design, all AD cases were amyloid positive and all control participants were amyloid negative based on CSF (n = 50), amyloid PET (n = 11), or both (n = 25). As expected, APOE ε4/ε4 carriers were more prevalent in AD cases (70.2% vs. 29.4% in control subjects) [@bib34]. Systolic blood pressure, pulse pressure, and mean arterial pressure were higher in control subjects (independent t-test, *P* = .02, *P* \< .01, and *P* = .01, respectively).Table 1Cohort characteristicsAlzheimer\'s diseaseControls*P* valueNumber4838Sex (m/f)25/2324/14.24[∗](#tbl1fnlowast){ref-type="table-fn"}Age65.4 (±8.1)60.6 (±5.0)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"}MMSE23 (±3)29 (±1)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"}Body mass index (kg/m^2^)24.4 (±3.1)26.2 (±4.1).32[†](#tbl1fndagger){ref-type="table-fn"}APOE ε4/ε4 genotype[§](#tbl1fnSection){ref-type="table-fn"} E4 homozygous, n (%)11 (23.4)1 (2.9)**\<.01**[\*](#tbl1fnlowast){ref-type="table-fn"} E4 heterozygous, n (%)22 (46.8)9 (26.5).05[∗](#tbl1fnlowast){ref-type="table-fn"} E4 negative, n (%)14 (29.8)24 (70.6)**\<.01**[∗](#tbl1fnlowast){ref-type="table-fn"}Blood pressure measures Systolic blood pressure (mmHg)148.9 (±17.5)139.0 (±18.4)**.02**[†](#tbl1fndagger){ref-type="table-fn"} Diastolic blood pressure (mmHg)84.2 (±10.1)82.8 (±9.1).55[†](#tbl1fndagger){ref-type="table-fn"} Pulse pressure (mmHg)64.7 (±12.6)56.2 (±12.5)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"} Mean arterial pressure (mmHg)84.4 (±64.1)59.3 (±83.5)**.01**[†](#tbl1fndagger){ref-type="table-fn"}MRI[\#](#tbl1fnhash){ref-type="table-fn"} Global cortical atrophy (GCA)1 (0-2)0 (0-1)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"} Medial temporal lobe atrophy (MTA)1.5 (0-2.5)0 (0-2)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"} Parietal cortical atrophy (PCA)1 (0-3)0 (0-1)**\<.01**[†](#tbl1fndagger){ref-type="table-fn"} Fazekas score1 (0-3)1 (0-2).08[‡](#tbl1fnddagger){ref-type="table-fn"} Microbleeds (n)0.1 (±0.4)2.7 (±14.6).35[‡](#tbl1fnddagger){ref-type="table-fn"} Lacunar infarcts (n)0 (±0)0.2 (±0.6)**.02**[‡](#tbl1fnddagger){ref-type="table-fn"}CSF[¶](#tbl1fnpara){ref-type="table-fn"} Aβ~1−42~ (ng/L)555.1 (±106.2)1162.3 (±200.0)**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"} Tau~-181~ (ng/L)711.5 (±304.5)242.2 (±85.7)**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"} pTau (ng/L)89.0 (±28.3)43.0 (±11.8)**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"} Tau~-181~/Aβ~1-42~ ratio1.3 (±0.5)0.2 (±0.1)**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"}Aβ PET[∗∗](#tbl1fnlowastlowast){ref-type="table-fn"} Positive/negative17/00/19**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"}Ophthalmological Intraocular pressure (mmHg)16.3 (±2.3)16.0 (±2.1).39[‡](#tbl1fnddagger){ref-type="table-fn"} Visual acuity (LogMAR)0.0 (±0.1)−0.1 (0.1)**\<.01**[‡](#tbl1fnddagger){ref-type="table-fn"}[^1][^2][^3][^4][^5][^6][^7][^8][^9]

3.1. Retinal vasculature parameters {#sec3.1}
-----------------------------------

### 3.1.1. Singapore I Vessel analysis (SIVA) {#sec3.1.1}

Seven retinal vascular parameters, previously shown to have good reproducibility [@bib32], showed no group differences between AD patients and control participants ([Fig. 2](#fig2){ref-type="fig"}A). Linear regression models assessing relationships between retinal vascular parameters and diagnosis, adjusted for age, and spherical equivalent (SE), showed no disease effect ([Table 2](#tbl2){ref-type="table"}). CRVE and FDa were found to be associated with age (β −0.25, *P* = .03 and β −0.28, *P* = .02, respectively) ([Table 2](#tbl2){ref-type="table"}). Adjusting analysis for systolic blood pressure, pulse pressure, or mean arterial pressure did not alter disease effects.Fig. 2Vascular parameters measured with fundus photography, EDI-OCT and OCTA. (A) Vascular parameters calculated using Singapore I Vessel Analysis (SIVA) software included central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), arteriole--venule ratio (AVR), fractal dimension of the arteriolar network (FDa), fractal dimension of the venular network (FDv), curvature tortuosity of the arterioles (cTORTa, values \*10^−5^), and curvature tortuosity of the venules (cTORTv, values \*10^−5^), compared between Alzheimer\'s disease participants (AD) and controls (HC). (B) Mean choroidal thickness measured in the macula (μm) in AD. (C) Vascular parameters from optical coherence tomography angiography (OCTA). Vessel density in the inner and outer ring of the Early Treatment in Diabetes Retinopathy Study grid and surface area (mm^2^) of the foveal avascular zone, compared between AD and control participants. Abbreviation: AD, Alzheimer\'s disease.Table 2Associations of vascular parameters with diagnosis, age, spherical equivalent, and quality factorRetinal vasculature parameterMean (SD)AgeSEADQuality factorADControlsβ*P* valueβ*P* valueβ*P* valueβ*P* valueSIVA CRAE106.1 (±7.5)107.9 (±12.1)−0.12.320.16.17−0.08.49n.a.n.a. CRVE161.6 (±12.2)168.1 (±15.6)−0.25**.03**0.19.08−0.13.27n.a.n.a. AVR0.66 (±0.05)0.64 (±0.06)0.13.27−0.03.780.05.68n.a.n.a. FDa1.16 (±0.04)1.17 (±0.04)−0.28**.02**0.15.17−0.05.68n.a.n.a. FDv1.15 (±0.04)1.15 (±0.04)−0.15.21−0.02.830.14.23n.a.n.a. cTORTa[∗](#tbl2fnlowast){ref-type="table-fn"}8.1 (±1.5)8.7 (±1.9)−0.05.690.04.74−0.15.22n.a.n.a. cTORTv[∗](#tbl2fnlowast){ref-type="table-fn"}8.5 (±1.7)8.4 (±1.2)−0.05.660.09.410.06.61n.a.n.a.EDI-OCT Choroidal thickness (μm)246.4 (±82.0)251.3 (±68.6)−0.34**\<.01**0.43**\<.01**0.14.24n.a.n.a.OCTA Vessel density inner ring17.3 (±1.5)17.4 (±1.2)0.07.490.08.370.02.850.77**\<.01** Vessel density outer ring17.4 (±1.3)17.8 (±1.1)−0.07.500.16.11−0.10.360.65**\<.01** Foveal avascular zone (mm^2^)0.24 (±0.06)0.26 (±0.08)0.04.810.07.60−0.14.33−0.04.81[^10][^11][^12]

### 3.1.2. Choroidal thickness analysis {#sec3.1.2}

Choroidal thickness in the macula showed no group differences between AD patients (246.4 μm, ±82.0) and control participants (251.3 μm, ±68.6) (independent t-test, *P* = .588) ([Fig. 2](#fig2){ref-type="fig"}B). Linear regression models assessing relationships between choroidal thickness and diagnosis, adjusted for age, and SE showed no disease effect (β 0.14, *P* = .24) but was associated with age (β −0.34, *P* = .01) and SE (β 0.43, *P* = .01) ([Table 2](#tbl2){ref-type="table"}). Adjusting analysis for different measures of blood pressure did not alter AD disease effects.

### 3.1.3. OCTA analysis {#sec3.1.3}

Vessel density in the inner and outer ring of the macula and the size of the FAZ showed no group differences between AD patients and control participants ([Fig. 2](#fig2){ref-type="fig"}C). Linear regression models assessing relationships between OCTA measures and diagnosis, adjusted for age, SE, and quality factor, showed no disease effect for vessel density in the inner ring (β 0.02, *P* = .85) or outer ring (β −0.10, *P* = .36), or FAZ (β −0.14, *P* = .33). Vessel density was, however, strongly associated with quality factor (inner ring \[β 0.77, *P* \< .001\], outer ring \[β 0.65, *P* \< .001\]), unlike FAZ (β −0.04, *P* = .81) ([Table 2](#tbl2){ref-type="table"}). Adjusting analysis for different measures of blood pressure did not alter AD disease effects.

3.2. Relationships between retinal vascular parameters and white matter hyperintensities {#sec3.2}
----------------------------------------------------------------------------------------

To assess relationships between retinal vasculature and intracerebral vascular changes, we correlated retinal vascular parameters with WMH scores on MRI (Fazekas score), adjusting for age and sex. Vessel density in the outer ring was found to be inversely associated with Fazekas score in AD participants (β −0.64, *P* \< .01), while curvature tortuosity of veins was inversely associated with Fazekas score in control subjects (β −0.56, *P* \< .01). No associations were found between other retinal vascular parameters and WMH scores ([Table 3](#tbl3){ref-type="table"}).Table 3Association between vascular parameters and WMHs in the total cohort and stratified for diagnosis, adjusted for age and sexRetinal vasculature parameterWhite matter hyperintensities (Fazekas score)TotalADControlsβ*P* valueβ*P* valueβ*P* valueSIVA CRAE0.03.83−0.05.790.01.98 CRVE−0.06.560−0.09.57−0.06.74 AVR0.07.570.01.970.09.61 FDa−0.11.40−0.12.48−0.14.47 FDv−0.01.940.02.92−0.21.29 cTORTa[∗](#tbl3fnlowast){ref-type="table-fn"}0.06.650.27.12−0.29.14 cTORTv[∗](#tbl3fnlowast){ref-type="table-fn"}−0.11.400.10.57**−0.56\<.01**EDI-OCT Choroidal thickness (μm)−0.07.58−0.06.720.02.92OCTA Vessel density inner ring−0.29.09−0.48.05−0.01.98 Vessel density outer ring**−0.32\<.05−0.64\<.01**0.18.40 Foveal avascular zone (mm^2^)−0.18.29−0.11.61−0.08.69[^13][^14][^15]

3.3. Relationships between retinal vascular parameters and MMSE, CSF Aβ~1-42~, and APOE ε4/ε4 genotype {#sec3.3}
------------------------------------------------------------------------------------------------------

Both adjusted and unadjusted for age and sex, no relationships between retinal vascular parameters and MMSE or CSF Aβ~1-42~ were observed. Comparing APOE ε4/ε4 carriers (n = 44) versus noncarriers (n = 37), irrespective of diagnosis, no differences in retinal vascular measures were found (independent samples t-test, all *P* \> .16).

3.4. Stratified analyses for early- versus late-onset Alzheimer\'s disease {#sec3.4}
--------------------------------------------------------------------------

Stratifying analyses of retinal vascular parameters, choroidal thickness, and OCTA measures for early- versus late-onset AD showed no group differences between the two disease group and controls, or between disease groups.

4. Discussion {#sec4}
=============

In this cross-sectional study using three imaging modalities, we found that there were no group differences in retinal vasculature between well-phenotyped, amyloid confirmed, AD and control cases after correction for age and sex. Stratifying cases for early- versus late-onset AD yielded similar results. Vessel density in the outer ring of the macula was found to be associated with WMH scores on MRI in AD participants, while curvature tortuosity of veins was associated with WMH scores in control subjects.

Our findings of unaltered retinal vascular caliber parameters on fundus photography in AD confirm a recent study that included biomarker confirmed AD cases (n = 29) based on amyloid PET imaging [@bib13]. In that same study, decreased FDa was observed in subcortical VCI patients [@bib13]. In contrast, other studies found differences in various retinal vascular parameters in different directions, that include decreased CRVE [@bib35], [@bib36], CRAE [@bib36], fractal dimension of the venular network [@bib35], [@bib36], [@bib37], FDa [@bib35], cTORTa [@bib37] and increased cTORTa [@bib35], and curvature tortuosity of the venules [@bib35] in AD patients compared to control participants. As these cohorts were larger (n \> 100 per patient group), it might indicate that the effect size of retinal vascular parameters is small and possibly remained undetected in our study. Alternatively, as previous studies used clinical diagnosis, cohorts could have consisted of dementia cases with a primarily vascular etiology or of cases with relevant vascular copathology. In those cases, retinal (micro)vasculature changes may represent vascular (co)pathology rather than AD-related changes. In the current cohort of amyloid-proven AD participants, clinical, neuroimaging, and fluid biomarkers showed clear disease effects, while an intrinsic AD effect on retinal vasculature was not detected. This queries the clinical use of retinal vascular caliber measurements as AD biomarker.

Using EDI-OCT, we did not observe choroidal thinning as previously described by a number of studies [@bib14], [@bib15], [@bib16], [@bib17], despite comparable group size and methodology. Not all studies adjusted their analyses for confounders such as age and spherical equivalent, which could have influenced reported findings, as these confounders showed significant effects on choroidal thickness in the present study contributing to choroidal thinning. Both uncorrected and corrected for age, we found no group differences in choroidal thickness. In addition, as our study did not directly take measurement time point into account, we were not able to control for known diurnal variation of choroidal thickness, that could have possibly influenced our findings, as variation in the order of 15-33 μm are observed over 24 hours [@bib38], [@bib39], [@bib40]. However, distribution of measurement time over the day was comparable between groups in our study, with a mean around midday in both groups.

In this study, describing OCTA measurements in amyloid-positive AD cases for the first time, we found no differences in vessel density and FAZ, while a strong effect of quality factor (QF) on vessel density measurements was observed \[β \> 0.65, *P* \< .001\] in scans with acceptable QFs (between 7 and 10). In contrast, previous studies described a decrease in vessel density and an increase in FAZ surface area in (preclinical) AD cases [@bib18], [@bib19], [@bib20]. However, as ophthalmological confounders, age, SE, and QF were not always taken into account, findings of those studies may represent an overestimation of true disease effects.

Given the thorough characterization of our participants, we were able to correlate retinal vascular measurements with WMH on MRI, Aβ~1-42~, Tau~-181~, and pTau in CSF and MMSE. Venular tortuosity was inversely correlated with WMH scores on MRI in control subjects, while in contrast an earlier study reported a positive correlation between WMH and venular tortuosity in control subjects [@bib32]. Confirming an earlier report, we found an inverse association between macular vessel density and WMH scores in AD, possibly reflecting microvasculature changes in chronic cerebral microinfarction. Similarly, in a recent report, a relation between WMH volume and fractal dimension was observed [@bib13]. These findings need confirmation in larger cohorts, including volumetric measures of WMHs. We found no associations between retinal vascular parameters and CSF biomarkers or MMSE.

A limitation of our study is its relatively small sample size and incomplete collection of all vascular markers, hampering sensitivity for small diseases effects on retinal vasculature. However, despite its relevance for understanding involvement of retinal vasculature in AD pathophysiology, the added value of these small effects for clinical use as a biomarker remain doubtful. As our cohort consisted of cases with relatively little vascular comorbidity, studies in VCI and mixed pathology are warranted to assess the use of retinal vascular parameters to detect vascular (co)-pathology in these populations.

5. Conclusion {#sec5}
=============

Using a multimodal retinal imaging approach in well-characterized amyloid status--confirmed AD and control cases, we found no evidence that retinal vasculature can be used as a noninvasive biomarker for AD.Research in Context1.Systematic Review: The authors searched PubMed for all publications assessing retinal microvasculature in Alzheimer\'s disease (AD). Well-phenotyped cohorts including amyloid status, white matter hyperintensities on magnetic resonance imaging and ophthalmological screening have not previously been examined.2.Interpretation: In this study, representing the largest cohort with amyloid proven AD cases, we show that retinal vasculature does not discriminate AD from control participants, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid measures, querying the use of retinal vasculature measurements as AD biomarker.3.Future directions: Future studies in cases with vascular cognitive impairment and mixed pathology are needed to assess the role of retinal vasculature as noninvasive biomarker for vascular (co)-pathology.
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[^1]: Significant associations (*P* \<.05) are displayed in bold.

[^2]: Abbreviations: APOE, apolipoprotein E; Aβ, amyloid beta; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; PET, positron emission tomography.

[^3]: Chi-square test.

[^4]: Independent samples t-test.

[^5]: Mann-Whitney U test.

[^6]: APOE ε4/ε4 genotype was available in 47 AD cases and 34 control subjects.

[^7]: MRI was available in 47 AD cases and 35 control subjects.

[^8]: CSF was available in 46 AD cases and 29 control subjects.

[^9]: Amyloid PET was available in 17 AD cases and 19 control subjects.

[^10]: Associations between vascular parameters, age, spherical equivalent, AD diagnosis, and quality factor from linear regression models. Means and standard deviations and uncorrected *P* values are given. Significant associations (*P* \<.05) are displayed in bold.

[^11]: Abbreviations: AD, Alzheimer\'s disease; AVR, arteriole-to-venule ratio; β, standardized beta; CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent; cTORTa, curvature tortuosity of the arterioles; cTORTv, curvature tortuosity of the venules; EDI-OCT, enhanced depth imaging optical coherence tomography; FDa, fractal dimension of the arteriolar network; FDv, fractal dimension of the venular network; n.a., not applicable; OCTA, optical coherence tomography angiography; SD, standard deviation; SE, spherical equivalent; SIVA, Singapore I Vessel analysis.

[^12]: Values \*10^−5^.

[^13]: Associations between vascular parameters and WMHs (Fazekas score) were assessed using linear regression, adjusted for age and sex. Standardized betas and uncorrected *P* values are given. Significant associations are indicated in bold.

[^14]: Abbreviations: AD, Alzheimer\'s disease; AVR, arteriole-to-venule ratio; β, standardized beta; CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent; cTORTa, curvature tortuosity of the arterioles; cTORTv, curvature tortuosity of the venules; EDI-OCT, enhanced depth imaging optical coherence tomography; FDa, fractal dimension of the arteriolar network; FDv, fractal dimension of the venular network; OCTA, optical coherence tomography angiography; SIVA, Singapore I Vessel analysis.

[^15]: Values \*10^−5^.
